Preview Mode Links will not work in preview mode

Mar 20, 2019

Oncology Today with Dr Neil Love: Breast Cancer Edition — A virtual roundtable discussion with noted investigators Charles Geyer and Sara Tolaney for a review of recent innovations in breast cancer medicine:

  • Design and results of the Phase III KATHERINE study investigating adjuvant T-DM1 versus trastuzumab for patients with residual invasive HER2-positive early breast cancer (0:00)
  • Side effects and tolerability of T-DM1 compared to trastuzumab (3:00)
  • Clinical implications of the KATHERINE trial (7:27)
  • Case (Dr Geyer): A 53-year-old woman with a locally advanced ER/PR-negative, HER2-positive, ulcerated infiltrating ductal carcinoma (IDC) experiences neuropathy after 6 cycles of neoadjuvant TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab) (12:52)
  • Management of the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy (15:36)
  • Case (Dr Tolaney): A 56-year-old woman with a 3.7-cm ER/PR-negative, HER2-positive IDC receives neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab) and adjuvant AC followed by trastuzumab/pertuzumab (20:01)
  • Selection of (neo)adjuvant treatment for patients with HER2-positive breast cancer (22:14)
  • Optimal treatment for early-stage HER2-positive breast cancer (28:05)
  • Role of the recently FDA-approved subcutaneous formulation of trastuzumab alone or in combination with chemotherapy for patients with HER2-positive BC (32:01)
  • Final results from the OlympiAD trial of olaparib versus standard chemotherapy; results from the EMBRACA trial comparing talazoparib to standard therapy for patients with germline BRCA mutations (34:52)
  • Case (Dr Geyer): A 31-year-old woman with metastatic ER/PR-positive, HER2-negative breast cancer receives ovarian suppression, fulvestrant and abemaciclib (39:45)
  • Use of PARP inhibitors for patients with metastatic breast cancer and BRCA mutations (41:51)
  • Case (Dr Tolaney): A 59-year-old woman with ER/PR-positive, HER2-negative metastatic breast cancer and a BRCA2 mutation receives olaparib as second-line therapy (45:18)
  • Sequencing of PARP inhibitors for patients with metastatic triple-negative breast cancer (TNBC) and BRCA mutations (49:52)
  • Ongoing PARTNER/PARTNERING studies evaluating olaparib with platinum-based neoadjuvant chemotherapy or as a part of novel combination approaches; investigation of neoadjuvant talazoparib for patients with TNBC and a germline BRCA mutation (51:49)
  • Ongoing Phase III OlympiA trial evaluating olaparib as adjuvant treatment for high-risk, HER2-negative breast cancer with a germline BRCA mutation (54:33)
  • Efficacy and safety of atezolizumab with nab paclitaxel for advanced TNBC in the Phase III IMpassion130 trial (56:57)
  • Choice of chemotherapy for patients with metastatic TNBC (59:49)
  • Perspective on overall survival for patients with advanced TNBC and PD-L1-positive tumors treated with atezolizumab and nab paclitaxel (1:4:42)
  • Case (Dr Tolaney): A 52-year-old woman develops pneumonitis while receiving pembrolizumab and eribulin for metastatic TNBC (1:7:09)
  • Endocrine toxicities associated with immune checkpoint inhibitors (1:9:26)
  • Ongoing Phase III NSABP-B-59/GBG-96-GeparDouze trial evaluating neoadjuvant chemotherapy with atezolizumab followed by adjuvant atezolizumab (1:10:34)
  • Ongoing Phase III ALEXANDRA/IMpassion030 study evaluating standard adjuvant chemotherapy with or without atezolizumab for early TNBC (1:13:10)
  • Emerging data with the HER2-selective tyrosine kinase inhibitor tucatinib for advanced HER2-positive metastatic breast cancer (1:14:48)
  • Comparison of the activity and tolerability of tucatinib to that of lapatinib and neratinib (1:19:15)
  • Efficacy and safety of the novel antibody-drug conjugate trastuzumab deruxtecan for HER2-positive breast cancer (1:21:46)
  • Results of the Phase III SOLAR-1 trial evaluating the PI3 kinase inhibitor alpelisib with fulvestrant for ER-positive advanced breast cancer (1:27:4)
  • NEO-ORB: A randomized Phase II study of neoadjuvant letrozole with alpelisib for HR-positive, HER2-negative breast cancer (1:31:47)

Select publications